PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD
Adequate primary and secondary prevention of thromboembolic complications is one of the main goals of management of patients with atrial fibrillation. Many years of practice and experience of warfarin use, unfortunately, did not lead to wider and more efficient use of anticoagulation therapy. New or...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2015-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/242 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227958077620224 |
|---|---|
| author | L. Y. Koroleva I. V. Kolesnichenko V. P. Nosov I. I. Gritsenko E. S. Timoschenko |
| author_facet | L. Y. Koroleva I. V. Kolesnichenko V. P. Nosov I. I. Gritsenko E. S. Timoschenko |
| author_sort | L. Y. Koroleva |
| collection | DOAJ |
| description | Adequate primary and secondary prevention of thromboembolic complications is one of the main goals of management of patients with atrial fibrillation. Many years of practice and experience of warfarin use, unfortunately, did not lead to wider and more efficient use of anticoagulation therapy. New oral anticoagulants devoid of drawbacks of warfarin, which prevented its prescription and long-term use, have appeared in the past few years. One of them, the most studied, with the largest list of indications for use, and very attractive, is rivaroxaban. |
| format | Article |
| id | doaj-art-a856b12b2ebf430c9b98d82c7968bea9 |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2015-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-a856b12b2ebf430c9b98d82c7968bea92025-08-23T10:00:18ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532015-09-0110330330610.20996/1819-6446-2014-10-3-303-306242PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGORODL. Y. Koroleva0I. V. Kolesnichenko1V. P. Nosov2I. I. Gritsenko3E. S. Timoschenko4Nizhny Novgorod State Medical AcademyCity Cardiology HospitalNizhny Novgorod State Medical AcademyCity Cardiology HospitalCity Cardiology HospitalAdequate primary and secondary prevention of thromboembolic complications is one of the main goals of management of patients with atrial fibrillation. Many years of practice and experience of warfarin use, unfortunately, did not lead to wider and more efficient use of anticoagulation therapy. New oral anticoagulants devoid of drawbacks of warfarin, which prevented its prescription and long-term use, have appeared in the past few years. One of them, the most studied, with the largest list of indications for use, and very attractive, is rivaroxaban.https://www.rpcardio.online/jour/article/view/242atrial fibrillationwarfarinrivaroxaban |
| spellingShingle | L. Y. Koroleva I. V. Kolesnichenko V. P. Nosov I. I. Gritsenko E. S. Timoschenko PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD Рациональная фармакотерапия в кардиологии atrial fibrillation warfarin rivaroxaban |
| title | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD |
| title_full | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD |
| title_fullStr | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD |
| title_full_unstemmed | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD |
| title_short | PREVENTION OF THROMBOEMBOLIC COMPLICATIONS IN ATRIAL FIBRILLATION - RAT POISON OR NEW ORAL ANTICOAGULANTS: DO WE HAVE A CHOICE, AND SHOULD WE BE AFRAID TO MAKE IT? FIRST CLINICAL EXPERIENCE WITH RIVAROXABAN IN NIZHNY NOVGOROD |
| title_sort | prevention of thromboembolic complications in atrial fibrillation rat poison or new oral anticoagulants do we have a choice and should we be afraid to make it first clinical experience with rivaroxaban in nizhny novgorod |
| topic | atrial fibrillation warfarin rivaroxaban |
| url | https://www.rpcardio.online/jour/article/view/242 |
| work_keys_str_mv | AT lykoroleva preventionofthromboemboliccomplicationsinatrialfibrillationratpoisonorneworalanticoagulantsdowehaveachoiceandshouldwebeafraidtomakeitfirstclinicalexperiencewithrivaroxabaninnizhnynovgorod AT ivkolesnichenko preventionofthromboemboliccomplicationsinatrialfibrillationratpoisonorneworalanticoagulantsdowehaveachoiceandshouldwebeafraidtomakeitfirstclinicalexperiencewithrivaroxabaninnizhnynovgorod AT vpnosov preventionofthromboemboliccomplicationsinatrialfibrillationratpoisonorneworalanticoagulantsdowehaveachoiceandshouldwebeafraidtomakeitfirstclinicalexperiencewithrivaroxabaninnizhnynovgorod AT iigritsenko preventionofthromboemboliccomplicationsinatrialfibrillationratpoisonorneworalanticoagulantsdowehaveachoiceandshouldwebeafraidtomakeitfirstclinicalexperiencewithrivaroxabaninnizhnynovgorod AT estimoschenko preventionofthromboemboliccomplicationsinatrialfibrillationratpoisonorneworalanticoagulantsdowehaveachoiceandshouldwebeafraidtomakeitfirstclinicalexperiencewithrivaroxabaninnizhnynovgorod |